Coursera Spring Sale
40% Off Coursera Plus Annual!
Grab it
Explore the dramatic transformation in lung cancer treatment outcomes through this comprehensive webinar presented by Professor Michael Thomas, head of thoracic oncology at the Thoraxklinik - University of Heidelberg. Discover how targeted treatments and immuno-oncology have revolutionized patient prognosis, moving from disappointing outcomes a decade ago to achieving over 50% five-year survival rates in specific subgroups with gene-fusions like ALK-fusion. Learn about the critical role of extended genetic diagnostics including qPCR, digital PCR, Sanger Sequencing, and NGS in identifying treatment options for metastatic non-small cell lung cancer (mNSCLC). Gain insights from Professor Thomas's extensive experience leading the German Lung Cancer Cooperative Group and his work designing large-scale phase III trials in trimodal treatment settings. Understand the molecular features and prerequisites of the tumor microenvironment that indicate predictive and prognostic impact in both locally advanced and metastatic treatment settings, and examine how these advances are reshaping the landscape of thoracic oncology care.
